1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. PFIZER INC.
Pfizer Inc.
XNYS: PFE
Turnaround Potential
Download real time
29.580.14(0.48%)
New 52W High in past week
28.6M
XNYS Volume

XNYS 16 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Dividend
Pfizer has an upcoming dividend of $0.430 per share due on 06 Nov 2026See details

Pfizer quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Pfizer share price target, revenues, EPS, net income and more

Pfizer quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
  • POSITIVE

    Quarterly Revenue Pfizer Jun-2026 Quarterly Revenue is $15,034 Million which is growth of 2.6% YoY.

  • NEGATIVE

    Quarterly Net Profit Pfizer Jun-2026 Quarterly Net Profit is $-248 Million which is growth of -108.5% YoY.

Pfizer Inc., Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
Operating Rev.
15,03414,45017,55716,65414,65313,71517,76417,70113,28314,87814,24913,23212,734
Cost Of Rev.
4,0923,5485,2724,1723,7782,8455,9095,2633,3003,3797,5639,2693,237
Gross Profit
10,94210,90212,28512,48210,87510,87011,85512,4389,98311,4996,6863,9639,497
⌄
7,4056,6348,5986,9557,1086,4458,6687,1547,7207,296-8,6577,1717,329
Operating Profit
3,5374,2683,6875,5273,7674,4253,1875,2842,2634,203-1,971-3,2082,168
⌄
-554-553-545-514-498-511-568-667-648-661-79-172-192
Profit Before Tax
-6533,170-1,6423,3343,0442,785-104,715-1033,421-4,129-3,3522,269
Tax
-407461-2-216141-189-421234-134293795-964-71
⌄
-2482,687-1,6483,5412,9102,9674104,465413,115-3,369-2,3822,327
Diluted NI Avail to Com Stockholders Ann.
-2482,687-1,6483,5412,9102,9674104,465413,115-3,369-2,3822,327
Basic EPS
-00.5-0.30.60.50.50.10.800.6-0.6-0.40.4
Diluted EPS After ExtraOrdinary
0.80.80.70.90.80.90.61.10.60.80.1-0.20.7
Number Of Shares End
5,6995,6915,6865,6855,6855,6755,6675,6675,6665,6575,6465,6465,646
Net Income Continuing Discontinued Operations
-2482,687-1,6483,5412,9102,9674104,465413,115-3,369-2,3822,327
Normalized Income
4,4404,2903,7864,9494,4345,2373,5926,0503,4004,674593-9683,839
Interest Income
113115166138156143171116130129609523316
Interest
667668711652654654739783778790-695508
Net Interest Income
-554-553-545-514-498-511-568-667-648-661--172-192
EBIT
-993,723-1,0973,8483,5423,2965585,3825454,082-4,050-3,1802,461
EBITDA
1,5235,3365905,5105,1674,9142,3497,1372,2765,818-2,380-1,6204,034
Reconciled Cost Of Rev.
3,6553,1184,8153,7333,3642,4385,4774,8202,8762,9517,5638,8882,848
Reconciled Depr.
1,6221,6131,6871,6621,6251,6181,7911,7551,7311,7361,6701,5601,573
Profit From Continuing Operations
-2202,683-1,6403,5512,9032,9734114,481313,128-3,335-2,3882,340
Normalized EBITDA
5,6006,1836,1297,5745,7476,4804,6867,5994,3436,1301,505-6344,606
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Pfizer competitor comparison and performance snapshot within industry

Pfizer annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Annual Revenue Pfizer Dec-2025 Annual Revenue is $62,579 Million which is growth of -1.6% YoY.

  • NEGATIVE

    Annual Net Profit Pfizer Dec-2025 Annual Net Profit is $7,771 Million which is growth of -3.2% YoY.

Pfizer Inc., Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
-14.6%
8.3%
 62,57963,62758,496100,33081,28841,90851,75053,64752,54652,82448,851
Cost Of Rev. Ann.
-22.4%
13.1%
17,08416,06717,85124,95434,34430,8218,69210,21911,24811,24012,3299,648
Gross Profit Ann.
-11%
7%
46,61146,51245,77633,54265,98650,46733,21641,53142,39941,30640,49539,203
Operating Exp. Ann.
0.5%
3.5%
29,59229,10530,83830,18328,71430,23224,45627,61027,35427,19926,76526,227
Operating Profit Ann.
-22.4%
14.7%
17,01917,40714,9383,35937,27220,2358,76013,92115,04514,10713,73012,976
⌄
-
-
-2,166-2,068-2,546-585-987-1,255-1,376-1,348-983-879-716-728
Other Exp. Ann.
-
-
 -7,819-4,369-1,716-1,5555,3311135,108-2,177-922-4,663-3,283
PBT Ann.
-40%
0.1%
4,2097,5208,0231,05834,72924,3117,49717,68211,88512,3058,3518,965
Tax Ann.
-
-
-164-266-28-1,1153,3281,8524771,384706-9,0491,1231,990
⌄
-37.2%
-4.2%
4,3327,7718,0312,11931,37221,9799,61616,27211,15221,3077,2146,959
Diluted NI Avail to Com Stockholders Ann.
-37.2%
-4.2%
4,3327,7718,0312,11931,37221,9799,61616,27311,15321,3087,2146,960
EPS Ann.
-37%
-3.8%
 1.41.40.45.63.91.72.91.93.61.21.1
Diluted EPS Ann.
-36.6%
-3.8%
 1.41.40.45.53.91.72.91.93.51.21.1
Number Of Shares End
0.4%
0.4%
 5,6865,6675,6465,6145,6135,5645,5335,7915,9646,0716,176
Total Exp. Ann.
-10.5%
6.4%
 45,17248,68955,13763,05861,05333,14837,82938,60238,43939,09435,875
Net Income Continuing Discontinued Operations Ann.
-37.2%
-4.2%
4,3327,7718,0312,11931,37221,9799,61616,27311,15321,3087,2156,960
Normalized Income Ann.
-21.3%
8%
17,46518,40617,71610,50137,71725,23612,50616,7339,94416,08514,76113,755
Interest Income Ann.
33.9%
52.5%
5326035451,6242513673226333391470471
Interest Ann.
29.2%
13%
2,6982,6713,0912,2091,2381,2911,4491,5741,3161,2701,1861,199
EBITDA Ann.
-26.5%
3.5%
12,95916,18017,5827,93340,78030,75713,65025,04019,25219,45314,82414,850
Reconciled Cost Of Rev. Ann.
-24.2%
14.3%
15,32114,34916,12423,39732,88929,3307,3518,8199,7579,72910,6288,219
Reconciled Depr. Ann.
9.2%
6.7%
6,5846,5927,0136,2905,0645,1914,7776,0106,3846,2695,7575,157
Profit From Continuing Operations Ann.
-37.2%
2.1%
4,3747,7878,0512,17231,40122,4597,02116,30211,18821,3557,2466,986
Normalized EBITDA Ann.
-17%
10.6%
25,48625,74522,71113,90445,04530,39615,56020,89322,94221,48121,23919,431
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
-1.6%
2Y CAGR
3.4%
3Y CAGR
-14.6%
5Y CAGR
8.3%
7Y CAGR
2.2%
10Y CAGR
2.5%
Total Revenue Annual is falling faster than historical averages.
Net Profit Ann.
1Y CHG
-3.2%
2Y CAGR
91.5%
3Y CAGR
-37.2%
5Y CAGR
-4.2%
7Y CAGR
-5%
10Y CAGR
1.1%
Net Profit Annual is falling slower than historical averages.
Operating Exp. Ann.
1Y CHG
-5.6%
2Y CAGR
-1.8%
3Y CAGR
0.5%
5Y CAGR
3.5%
7Y CAGR
0.9%
10Y CAGR
1%
Operating Expenses Annual Cr is falling faster than historical averages.

Pfizer balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Total Shareholders Fund Pfizer Dec-2025 Total Shareholders Fund is $86,476 Million which is growth of -2.0% YoY.

  • NEGATIVE

    Total Assets Pfizer Dec-2025 Total Assets is $208,160 Million which is growth of -2.5% YoY.

Pfizer Inc., Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
1.8%
6.2%
208,160213,396226,501197,205181,476154,229167,489159,422171,797171,615167,460
⌄
6.2%
6%
121,385124,899137,213101,289104,01490,756104,04295,664100,141111,775102,462
⌄
-3.3%
6.5%
86,47688,20389,01495,66177,20163,23863,12663,38871,28759,52064,694
Total Capitalization Ann.
4.9%
8.3%
147,283144,906149,513127,586111,95898,80997,79295,836103,97489,94393,538
Tangible Assets Ann.
-
-
-38,518-35,736-43,6699162,847-14,811-30,879-25,215-33,384-47,553-23,880
Working Capital Ann.
-13.4%
-8.4%
5,9147,363-4,4619,12117,0229,147-4,50118,06810,7147,83414,405
Invested Capital Ann.
4.8%
8.2%
150,437151,852159,859130,531114,199101,512113,965104,653113,893100,607103,672
Tangible Book Value Ann.
-
-
-38,518-35,736-43,6699162,847-14,811-30,896-25,234-33,405-47,577-23,906
Borrowings Ann.
22.4%
10.8%
63,96163,64970,84534,87036,99838,27450,83941,26542,60641,08738,978
Net Debt Ann.
22.2%
11.5%
62,81962,60667,99234,45435,05436,49049,53440,12641,26438,49235,337
Share Issued Ann.
0.4%
0.5%
9,6219,5939,5629,5199,4719,4079,3699,3329,2759,2309,178
Number Of Shares End
0.4%
0.4%
5,6865,6675,6465,6145,6135,5645,5335,7915,9646,0716,176
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Assets Ann.
1Y CHG
-2.5%
2Y CAGR
-4.1%
3Y CAGR
1.8%
5Y CAGR
6.2%
7Y CAGR
3.9%
10Y CAGR
2.2%
Total Assets Annual is falling faster than historical averages.
Total Current Liabilities Ann.
1Y CHG
-14%
2Y CAGR
-12%
3Y CAGR
-4.3%
5Y CAGR
7.4%
7Y CAGR
2.2%
10Y CAGR
2.3%
Total Current Liabilities Annual Cr is falling faster than historical averages.
Total ShareHolders Funds Ann.
1Y CHG
-2%
2Y CAGR
-1.4%
3Y CAGR
-3.3%
5Y CAGR
6.5%
7Y CAGR
4.5%
10Y CAGR
2.9%
Total ShareHolders Funds Annual is falling faster than historical averages.

Pfizer ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Book Value Per Share Pfizer Book Value Per Share is $15 which is growth of -2.2% YoY.

  • NEUTRAL

    ROE Pfizer ROE is 0% which is growth of 0% YoY.

Pfizer Inc., Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
RoA Ann. %
-
-
-3.65%1.00%16.57%13.09%5.98%9.96%6.73%12.41%4.26%4.13%
ROE Ann. %
-
-
-9.06%2.29%36.30%31.30%15.22%25.72%16.56%32.58%11.62%10.24%
ROIC %
-
-
-0.6-43.20.7-0.1-0.211.40.9-0.1
OPM Ann. %
-9.2%
5.9%
27.82%23.48%5.74%37.15%24.89%20.90%26.90%28.04%26.85%25.99%26.56%
Inventory Turnover Ratio Ann.
-
-
-1.72.63.83.61.11.31.51.61.71.5
Asset Turnover Ann. %
-
-
-0.30.30.50.50.30.30.30.30.30.3
Working Capital Turnover Ann.
-1.2%
18.2%
10.68.6-13.1114.84.6-11.534.96.73.4
Quick Ratio Ann.
-
-
-0.80.60.91.10.90.6110.91.2
Current Ratio Ann.
-
-
-1.20.91.21.41.40.91.61.41.31.5
Interest Coverage Ratio Ann.
-
-
-3.61.529.119.86.212.21010.788.5
LT Debt To Equity Ann.
-
-
-0.60.70.30.50.60.60.50.50.50.5
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Pfizer cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Cash From Operating Activity Pfizer Dec-2025 Cash From Operating Activity is $11,705 Million which is growth of -8.1% YoY.

  • POSITIVE

    Net Cash Flow Pfizer Dec-2025 Net Cash Flow is $51 Million which is growth of 102.9% YoY.

Pfizer Inc., Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
-26.3%
2%
11,70512,7438,70129,26732,92310,58612,58815,82816,46815,90114,512
⌄
-
-
-1,3512,654-32,277-15,783-22,533-4,189-3,9464,526-4,741-7,812-2,980
⌄
-
-
-10,303-17,14026,067-14,834-9,816-21,639-8,486-20,440-13,035-8,921-10,233
Cash Plus Cash Eqv. End Of Year Ann.
36.8%
-8.1%
1,1971,1072,9174681,9831,8251,3501,2251,3422,5953,641
Net Increase In Cash Plus Cash Eqv.s Ann.
-
-36.7%
49-1,7442,489-1,350217483157-90-1,306-8311,298
Cash Plus Cash Eqv. Begin Of Year Ann.
-17.7%
-3.9%
1,1072,9174681,9831,8251,3501,2251,4312,5953,6413,343
Income Tax Paid Supplemental Data Ann.
-15.8%
8.3%
4,6883,6053,1477,8677,4273,1533,6643,6552,4892,5212,383
Interest Paid Supplemental Data Ann.
23.8%
10.8%
2,7393,2272,2151,4421,4671,6411,5871,3111,5181,4511,302
Capex Ann.
-
-
-2,629-2,909-3,907-3,236-2,711-2,791-2,594-2,196-2,217-1,999-1,496
Issuance Of Capital Stock Ann.
-
-
-----------
Issuance Of Debt Ann.
35.5%
-11.2%
9,6788,90738,5173,89199717,57423,9488,68515,13918,4488,274
Repayment Of Debt Ann.
-
-
-9,752-16,066-2,572-7,407-2,100-30,329-15,184-9,620-16,144-15,875-6,968
Repurchase Of Capital Stock Ann.
-
-
--2,000-8,865-12,198-5,000-5,000-6,160
Free Cash Flow Ann.
-29.6%
3.1%
9,0769,8344,79426,03130,2127,7959,99413,63214,25113,90213,016
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Cash from Operating Act. Ann.
1Y CHG
-8.1%
2Y CAGR
16%
3Y CAGR
-26.3%
5Y CAGR
2%
7Y CAGR
-4.2%
10Y CAGR
-2.1%
Cash from Operating Activity Annual is falling faster than historical averages.
×